Advancements in Bioequivalence & Bioavailability

The Coming Age of Particle Vaccines

  • Open or Close Walpita Pramila*

    Department of Tropical Medicine, Medical Microbiology and Pharmacology John A. Burns School of Medicine, USA

    *Corresponding author: Walpita Pramila, Department of Tropical Medicine, Medical Microbiology and Pharmacology John A, Burns School of Medicine, 651 Ilalo Street, BSB 320, Hawai, USA

Submission: February 12, 2018; Published: April 04, 2018

DOI: 10.31031/ABB.2018.01.000505

ISSN 2640-9275
Volume1 Issue1


Vaccine technology is needed to combat unexpected uncontrolled viral disease outbreaks rapidly. It is desired to have a vaccine ready if possible within less than three months in such situations. The traditional way of making vaccines such as inactivated or live attenuated viruses in general are highly effective, in some cases they fail to provide adequate immunogenicity, safety or even cause adverse events. In the case of live attenuated vaccines, achieving a stable optimally attenuated virus is often difficult and there is the potential for reversion. Transmission to the immunecompromised individuals is an additional concern. Inactivated vaccines run the risk of inducing enhanced disease. Additionally, it is not feasible for either an inactivated or an attenuated vaccine to be ready in a short time. Subunit vaccines have not been successful to date for human use. Various techniques of engineering the virus and vectored approaches are being also attempted.

Get access to the full text of this article